Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony W Tolcher

Showing results (11-20 of 123) with videos related to

Pageof 13
Sort By:
The Journal of Urology|November 7, 2006
Management of high risk metastatic prostate cancer: the case for novel therapiesTimothy C Brand, Anthony W Tolcher
Future Oncology (London, England)|January 25, 2018
Improving combination cancer therapy: the CombiPlex<sup>®</sup> development platformAnthony W Tolcher, Lawrence D Mayer
Molecular Cancer Therapeutics|January 4, 2018
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsAnthony W Tolcher, Wei Peng, Emiliano Calvo
Seminars in Oncology|November 13, 2003
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinomaJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Breast Cancer Research : BCR|June 10, 2003
The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2026
Advancing Antibody-Drug Conjugates: Current Perspectives and Future DirectionsJulian David Etessami, Carmine Valenza, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|May 7, 2011
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumorsMuhammad Wasif Saif, John Sarantopoulos, Amita Patnaik, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2007
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safetyFeng Guo, Stephen P Letrent, Pamela N Munster, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2013
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumoursJean Charles Soria, Christophe Massard, Vladimir Lazar, et al.
Cancer Chemotherapy and Pharmacology|January 11, 2012
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trialLori Berk, Monica M Mita, Jeff Kreisberg, et al.
Pageof 13

Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
The Journal of Urology|November 7, 2006
Management of high risk metastatic prostate cancer: the case for novel therapiesTimothy C Brand, Anthony W Tolcher
Future Oncology (London, England)|January 25, 2018
Improving combination cancer therapy: the CombiPlex<sup>®</sup> development platformAnthony W Tolcher, Lawrence D Mayer
Molecular Cancer Therapeutics|January 4, 2018
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsAnthony W Tolcher, Wei Peng, Emiliano Calvo
Seminars in Oncology|November 13, 2003
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinomaJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Breast Cancer Research : BCR|June 10, 2003
The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2026
Advancing Antibody-Drug Conjugates: Current Perspectives and Future DirectionsJulian David Etessami, Carmine Valenza, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|May 7, 2011
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumorsMuhammad Wasif Saif, John Sarantopoulos, Amita Patnaik, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2007
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safetyFeng Guo, Stephen P Letrent, Pamela N Munster, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2013
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumoursJean Charles Soria, Christophe Massard, Vladimir Lazar, et al.
Cancer Chemotherapy and Pharmacology|January 11, 2012
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trialLori Berk, Monica M Mita, Jeff Kreisberg, et al.
Pageof 13